Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immucor HEA BeadChip Product Wins CE Mark Approval
Immucor’s HEA BeadChip product, through its multiplex DNA analysis, performs extended typing of 32 red blood cell antigens simultaneously. The CE mark covers all antigens tested by the
Immucor’s HEA BeadChip product, through its multiplex DNA analysis, performs extended typing of 32 red blood cell antigens simultaneously. The CE mark covers all antigens tested by the
GSK stated that the FDA, in making its final decision, is expected to consider the recommendation of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety
Amorfix’ antibodies which showed efficacy in animal models of ALS will now be developed and prepared for clinical trials by Biogen Idec at its expense. As per the
Fondaparinux is a generic version of GlaxoSmithKline’s Arixtra. Fondaparinux is an anticoagulant (blood thinner) used for the treatment and prevention of deep vein thrombosis (DVTs). As per the
The new research is expected to be conducted in Samsung Medical Center in Seoul. Pfizer said that it expanded into the market for targeted anticancer agents with the
Mylan is not assuming any of Bioniche Pharma’s outstanding debt or acquiring the company’s cash as part of the transaction. Mylan expects to finance this transaction using a
Nabumetone product is bioequivalent and, therefore, therapeutically equivalent to Nabumetone tablets. Nabumetone belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs), which are used to reduce
Under the terms of the agreement, ValaMed will be involved in the development of chemo-sensitivity assays of cancerous tissues. The company is developing assessment methodologies that will allow
Biotage said that based on high-performance, Molecularly Imprinted Polymers (MIPs), the 4 different screening plates deliver 128 selective resins. Biotage said that it would provide professional MIPs technical
Merck agreed to acquire Millipore on February 28, 2010 for $107 in cash per share of Millipore common stock. The closing follows the approval of the acquisition by